Recent Advances in Green Chemistry Approaches for the Sustainable Synthesis of Pharmaceutical Intermediates

Abstract

The pharmaceutical industry stands at a critical juncture regarding environmental sustainability. Conventional synthetic routes for active pharmaceutical ingredients (APIs) and intermediates generate substantial waste, averaging 35–503 kg per kilogram of API, depending on molecular complexity, with cumulative annual environmental and economic costs exceeding $20 billion globally. This unsustainable trajectory, combined with the strengthening of regulatory frameworks and corporate environmental commitments, has catalysed a fundamental transformation in the philosophy of pharmaceutical synthesis. Green chemistry, defined as the design of chemical products and processes that reduce or eliminate the generation of hazardous substances, has evolved from an academic aspiration into an essential industrial competency. This comprehensive review synthesises recent advances (2022–2025) across seven primary technological paradigms: biocatalysis and enzymatic synthesis, continuous-flow chemistry, innovative solvent systems (supercritical fluids and ionic liquids), mechanochemistry, photoredox catalysis, electrochemical synthesis, and renewable feedstock integration. Through systematic analysis of regulatory drivers, mechanistic innovations, industrial case studies, and quantitative performance metrics (atom economy, E-factor, process mass intensity), this review demonstrates that pharmaceutical intermediates synthesised via green methodologies now routinely achieve 50–90% waste reduction, superior stereochemical control, and improved economic viability compared to legacy synthetic routes. Integration of artificial intelligence, digital process modelling, and hybrid catalytic platforms represents the frontier of this transformation, promising unprecedented efficiency gains and environmental stewardship for pharmaceutical manufacturing in the coming decade.